Cargando…
Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study
Sarcopenia often affects patients with various types of cancer, and has been reported to affect patient prognosis and therapeutic effects. However, to the best of our knowledge, there are no reports on the relationship between gemcitabine plus nab-paclitaxel combination therapy (GnP) and sarcopenia...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494620/ https://www.ncbi.nlm.nih.gov/pubmed/36238838 http://dx.doi.org/10.3892/ol.2022.13495 |
_version_ | 1784793832820310016 |
---|---|
author | Tozuka, Yuichiro Ueno, Makoto Kobayashi, Satoshi Morimoto, Manabu Fukushima, Taito Sano, Yusuke Kawano, Kuniyuki Hanaoka, Akane Tezuka, Shun Asama, Hiroyuki Moriya, Satoshi Morinaga, Soichiro Ohkawa, Shinichi Maeda, Shin |
author_facet | Tozuka, Yuichiro Ueno, Makoto Kobayashi, Satoshi Morimoto, Manabu Fukushima, Taito Sano, Yusuke Kawano, Kuniyuki Hanaoka, Akane Tezuka, Shun Asama, Hiroyuki Moriya, Satoshi Morinaga, Soichiro Ohkawa, Shinichi Maeda, Shin |
author_sort | Tozuka, Yuichiro |
collection | PubMed |
description | Sarcopenia often affects patients with various types of cancer, and has been reported to affect patient prognosis and therapeutic effects. However, to the best of our knowledge, there are no reports on the relationship between gemcitabine plus nab-paclitaxel combination therapy (GnP) and sarcopenia in patients with unresectable pancreatic cancer. The present study analyzed the relationship between overall survival (OS), progression-free survival (PFS), response rate, disease control rate, adverse events (AEs) and sarcopenia in patients with pancreatic cancer treated with GnP. A total of 121 consecutive patients with advanced pancreatic cancer who received GnP as first-line chemotherapy between January 2015 and December 2017 were retrospectively analyzed. GnP consisted of 1,000 mg/m(2) gemcitabine and 125 mg/m(2) nab-paclitaxel, which were administered on days 1, 8 and 15 every 4 weeks. The skeletal muscle index (SMI) was calculated using bioimpedance analysis (BIA) as an index of sarcopenia prior to GnP. The patients were divided into sarcopenia (n=41) and non-sarcopenia (n=80) groups using cutoff values of 8.87 and 6.42 kg/m(2) for male and female patients, respectively. The sarcopenia and non-sarcopenia groups had a median OS of 8.1 and 13.9 months, respectively [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.53-1.20], and a median PFS of 4.3 and 6.3 months, respectively (HR 0.63; 95% CI 0.42-0.95). The response and disease controls rate were not statistically different between the groups (20 vs. 32%, P=0.20; 81 vs. 80%, P=1.0). In addition, comparison of common grade 3 and 4 AEs between the two groups revealed no statistically significant differences. In conclusion, the results of the present study indicated that SMI obtained by BIA may be a predictor of treatment response and prognosis in patients with advanced pancreatic cancer who undergo GnP. |
format | Online Article Text |
id | pubmed-9494620 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | D.A. Spandidos |
record_format | MEDLINE/PubMed |
spelling | pubmed-94946202022-10-12 Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study Tozuka, Yuichiro Ueno, Makoto Kobayashi, Satoshi Morimoto, Manabu Fukushima, Taito Sano, Yusuke Kawano, Kuniyuki Hanaoka, Akane Tezuka, Shun Asama, Hiroyuki Moriya, Satoshi Morinaga, Soichiro Ohkawa, Shinichi Maeda, Shin Oncol Lett Articles Sarcopenia often affects patients with various types of cancer, and has been reported to affect patient prognosis and therapeutic effects. However, to the best of our knowledge, there are no reports on the relationship between gemcitabine plus nab-paclitaxel combination therapy (GnP) and sarcopenia in patients with unresectable pancreatic cancer. The present study analyzed the relationship between overall survival (OS), progression-free survival (PFS), response rate, disease control rate, adverse events (AEs) and sarcopenia in patients with pancreatic cancer treated with GnP. A total of 121 consecutive patients with advanced pancreatic cancer who received GnP as first-line chemotherapy between January 2015 and December 2017 were retrospectively analyzed. GnP consisted of 1,000 mg/m(2) gemcitabine and 125 mg/m(2) nab-paclitaxel, which were administered on days 1, 8 and 15 every 4 weeks. The skeletal muscle index (SMI) was calculated using bioimpedance analysis (BIA) as an index of sarcopenia prior to GnP. The patients were divided into sarcopenia (n=41) and non-sarcopenia (n=80) groups using cutoff values of 8.87 and 6.42 kg/m(2) for male and female patients, respectively. The sarcopenia and non-sarcopenia groups had a median OS of 8.1 and 13.9 months, respectively [hazard ratio (HR) 0.79; 95% confidence interval (CI) 0.53-1.20], and a median PFS of 4.3 and 6.3 months, respectively (HR 0.63; 95% CI 0.42-0.95). The response and disease controls rate were not statistically different between the groups (20 vs. 32%, P=0.20; 81 vs. 80%, P=1.0). In addition, comparison of common grade 3 and 4 AEs between the two groups revealed no statistically significant differences. In conclusion, the results of the present study indicated that SMI obtained by BIA may be a predictor of treatment response and prognosis in patients with advanced pancreatic cancer who undergo GnP. D.A. Spandidos 2022-09-08 /pmc/articles/PMC9494620/ /pubmed/36238838 http://dx.doi.org/10.3892/ol.2022.13495 Text en Copyright: © Tozuka et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
spellingShingle | Articles Tozuka, Yuichiro Ueno, Makoto Kobayashi, Satoshi Morimoto, Manabu Fukushima, Taito Sano, Yusuke Kawano, Kuniyuki Hanaoka, Akane Tezuka, Shun Asama, Hiroyuki Moriya, Satoshi Morinaga, Soichiro Ohkawa, Shinichi Maeda, Shin Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study |
title | Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study |
title_full | Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study |
title_fullStr | Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study |
title_full_unstemmed | Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study |
title_short | Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: A retrospective study |
title_sort | prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus nab-paclitaxel: a retrospective study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494620/ https://www.ncbi.nlm.nih.gov/pubmed/36238838 http://dx.doi.org/10.3892/ol.2022.13495 |
work_keys_str_mv | AT tozukayuichiro prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT uenomakoto prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT kobayashisatoshi prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT morimotomanabu prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT fukushimataito prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT sanoyusuke prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT kawanokuniyuki prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT hanaokaakane prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT tezukashun prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT asamahiroyuki prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT moriyasatoshi prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT morinagasoichiro prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT ohkawashinichi prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy AT maedashin prognosticsignificanceofsarcopeniaasdeterminedbybioelectricalimpedanceanalysisinpatientswithadvancedpancreaticcancerreceivinggemcitabineplusnabpaclitaxelaretrospectivestudy |